Search Within

Daniel C Danila

Formats
  1. Meeting Abstract (88)
  2. Journal Article (62)
  3. Book Section (1)
  4. Correspondence (1)
  5. Miscellaneous (1)
  6. Review (1)
Groups
  1. Department of Medicine (154)
  2. Genitourinary Oncology Service (154)
  3. Solid Tumor Oncology Division (154)
  4. GSK Faculty (50)
  5. Hematologic Malignancies, Division of (48)
  6. Epidemiology and Biostatistics (42)

More Groups

People
  1. Howard Scher (111)
  2. Michael Morris (53)
  3. Martin Fleisher (48)
  4. Dana Rathkopf (45)
  5. Susan Slovin (39)
  6. Aseem Anand (33)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Clinical Cancer Research (11)
  3. Annals of Oncology (10)
  4. Cancer Research (7)
  5. European Urology (5)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (78)
  2. American Association for Cancer Research (20)
  3. Elsevier Science, Inc. (15)
  4. Oxford University Press (11)
  5. Elsevier Inc. (8)
  6. Society of Nuclear Medicine (3)

More Publishers

Results (154)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W.; Danila, D.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P.; Armstrong, A. J.; Pook, D.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)
    Meeting Abstract

    Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
    Meeting Abstract

    Guo, S. S.; Halabi, S.; Nanus, D. M.; George, D. J.; Antonarakis, E. S.; Danila, D. C.; Szmulewitz, R. Z.; McDonnell, D. P.; Norris, J. D.; Lu, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Cancer associated macrophage-like cells are prognostic for highly aggressive prostate cancer in both the non-metastatic and metastatic settings
    Journal Article

    Gironda, D. J.; Bergan, R. C.; Alpaugh, R. K.; Danila, D. C.; Chuang, T. L.; Hurtado, B. Y.; Ho, T.; Adams, D. L.
    Cancers (2023)

    Fulltext@MSK | Save
  • Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
    Journal Article

    Smith, M. R.; Sandhu, S.; George, D. J.; Chi, K. N.; Saad, F.; Thiery-Vuillemin, A.; Stàhl, O.; Olmos, D.; Danila, D. C.; Gafanov, R.; more...
    Journal of Managed Care & Specialty Pharmacy (2023)

    Fulltext@MSK | Save
  • Clinical impact of a rapid genetic testing model for advanced prostate cancer patients
    Journal Article

    Breen, K. E.; Symecko, H.; Spielman, K.; Gebert, R.; Shah, I. H.; Pundock, S.; Batson, M.; Narayan, V. K.; Stadler, Z. K.; Autio, K. A.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Gupta, S.; Yang, Q.; Halabi, S.; Tubbs, A.; Gore, Y.; George, D. J.; Nanus, D. M.; Antonarakis, E. S.; Danila, D.; Szmulewitz, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Waterhouse, D. M.; Appleman, L. J.; Pook, D. W.; Matsubara, N.; Dorff, T. B.; Lee, J. L.; Armstrong, A. J.; Kim, M.; Horvath, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save